GoodRx Holdings (GDRX) Change in Accured Expenses (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Change in Accured Expenses data on file, last reported at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 1025.16% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 291.84% YoY), and the FY2025 full-year result was $1.2 million, up 183.33% from the prior year.
• Change in Accured Expenses grew to $1.7 million in Q1 2026, from -$41.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $41.9 million in Q3 2025 to a low of -$41.0 million in Q4 2025.
• A 5-year average of $1.0 million and a median of $179000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 23557.75% in 2022, while the deepest fall reached 4108.62% in 2022.
• Tracing GDRX's Change in Accured Expenses over 5 years: stood at -$7.8 million in 2022, then jumped by 38.27% to -$4.8 million in 2023, then jumped by 58.03% to -$2.0 million in 2024, then slumped by 1928.83% to -$41.0 million in 2025, then soared by 104.25% to $1.7 million in 2026.
• Business Quant data shows GDRX's Change in Accured Expenses at $1.7 million in Q1 2026, -$41.0 million in Q4 2025, and $41.9 million in Q3 2025.